Citigroup
RXII

Citigroup’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Citigroup’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-30,071
Closed -$11K – 7521
2016
Q3 		$11K Buy
30,071
+1,385
+5% +$507 ﹤0.01% 6518
2016
Q2 		$14K Sell
28,686
-131,565
-82% -$64.2K ﹤0.01% 6401
2016
Q1 		$218K Buy
160,251
+100,143
+167% +$136K ﹤0.01% 5007
2015
Q4 		$89K Buy
60,108
+49,882
+488% +$73.9K ﹤0.01% 5469
2015
Q3 		$16K Sell
10,226
-2,075
-17% -$3.25K ﹤0.01% 6190
2015
Q2 		$21K Sell
12,301
-6,097
-33% -$10.4K ﹤0.01% 6088
2015
Q1 		$26K Sell
18,398
-12,137
-40% -$17.2K ﹤0.01% 5953
2014
Q4 		$46K Buy
30,535
+16,102
+112% +$24.3K ﹤0.01% 5754
2014
Q3 		$29K Sell
14,433
-10,672
-43% -$21.4K ﹤0.01% 5681
2014
Q2 		$77K Sell
25,105
-3,411
-12% -$10.5K ﹤0.01% 4867
2014
Q1 		$72K Sell
28,516
-27,539
-49% -$69.5K ﹤0.01% 5250
2013
Q4 		$278K Buy
56,055
+48,744
+667% +$242K ﹤0.01% 4365
2013
Q3 		$16K Buy
7,311
+7,111
+3,556% +$15.6K ﹤0.01% 6032
2013
Q2 		$0 Buy
+200
New – ﹤0.01% 6900

Citigroup's RXII Position: Q4 2016 in Review

Citigroup sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 30,071 shares — an estimated $11K sold.

Citigroup first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $278K in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

  • Citigroup reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
  • Citigroup sold 30,071 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $11K.
  • Citigroup first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
  • Citigroup's GALENA BIOPHARMA INC COM position peaked at $278K in Q4 2013.
  • 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.